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ABSTRACT
Objectives: Spinal cord stimulation (SCS) is an established treatment of chronic neuropathic pain. Although a temporary SCS
screening trial is widely used to determine suitability for a permanent implant, its evidence base is limited. The recent TRIAL-
STIM study (a randomized controlled trial at three centers in the United Kingdom) found no evidence that an SCS screening
trial strategy provides superior patient outcomes as compared with a no trial approach. As part of the TRIAL-STIM study, we
undertook a nested qualitative study to ascertain patients’ preferences in relation to undergoing a screening trial or not.
Materials and Methods: We interviewed 31 patients sampled from all three centers and both study arms (screening trial/no
trial) prior to SCS implantation, and 23 of these patients again following implantation (eight patients were lost to follow-up).
Interviews were undertaken by telephone and audio-recorded, then transcripts were subject to thematic analysis. In addition,
participants were asked to state their overall preference for a one-stage (no screening trial) versus two-stage (screening trial)
implant procedure on a five-point Likert scale, before and after implantation.
Results: Emergent themes favoured the option for a one-stage SCS procedure. Themes identified include: saving time (off
work, in hospital, attending appointments), avoiding the worry about having “loose wires” in the two-stage procedure, having
only one period of recovery, and saving NHS resources. Participants’ rated preferences show similar support for a one-stage
procedure without a screening trial.
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Conclusions: Our findings indicate an overwhelming preference among participants for a one-stage SCS procedure both
before and after the implant, regardless of which procedure they had undergone. The qualitative study findings further sup-
port the TRIAL-STIM RCT results.
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INTRODUCTION
Neuropathic pain is a complex and disabling condition that
affects up to 8% of the adult population (1) with substantial
impact on health-related quality-of-life (HRQoL) (2,3). Up to 50%
of patients with neuropathic pain fail to obtain pain relief from
analgesic medication (4).
Spinal cord stimulation (SCS) is an effective treatment for
severe neuropathic pain (5). In Europe, North America, and many
other countries, patients are required by clinical guidance to
undergo a successful SCS screening trial to be able to receive the
more expensive SCS implant (6,7). An expert panel defined a suc-
cessful trial as the patient reporting ≥50% pain relief with stable
or reduced pain medication (7).
Screening trials give patients a short flavor of living with SCS therapy.
They also allow patients and physicians a baseline evaluation of the
pain relief experienced and electrical current consumption required
from the device, which may impact the choice of pulse generator
implanted (8). However, screening trials require duplication of proce-
dures, thereby consuming more healthcare resources in operating
room time and a second admission (9). Moreover, prolonged home
SCS screening trials expose patients to a higher risk of infection (10).
Published studies to date have questioned the prognostic value
of screening trials (11). While screening trials allow patients to expe-
rience at first hand the effects of SCS therapy before deciding to
receive a permanent implant, they are costly, necessitate procedure
duplication, are associated with an increased risk of infection and
may not appropriately represent therapeutic long-term outcomes.
The recommendation that all candidates for SCS should undergo a
screening trial prior to permanent SCS implantation is largely based
on expert opinion rather than firm evidence.
MATERIALS AND METHODS
This embedded qualitative study set out to assess the prefer-
ences and experiences of patients within the TRIAL-STIM study
randomized controlled trial (ISRCTN, ISRCTN60778781). The proto-
col for the TRIAL-STIM study (12) and diagnostic performance,
effectiveness, and cost effectiveness findings were published else-
where (13). The following study methods are presented in accor-
dance with the Consolidated Criteria for Reporting Qualitative
Research (COREQ) framework (14).
Inclusion Criteria
Participants were approached from all three TRIAL-STIM study
sites, after they had been found eligible to take part in the main
study. The principle inclusion criteria were: aged 18 years or over;
clinically a candidate for SCS as per NICE TA159 guidance; and
having persistent neuropathic pain for more than six months
despite conventional medical and surgical management, of an
intensity of at least five on a numerical rating scale (scores 0–10).
Participants were randomized 1:1 either to receive a screening
trial of SCS followed by full implant in a two-stage procedure or
to proceed directly to an SCS implant in a one-stage procedure.
A purposive sampling strategy was utilized with a view to
including two groups of participants:
1. those undergoing a two-stage procedure (a trial period
followed by implantation—usual care) TG; and
2. those undergoing a one-stage procedure (implantation only—
intervention) NTG.
Recruitment
Participants were invited to take part in the qualitative study as
a separate and optional element of the main clinical trial, with an
additional section on the consent form indicating their agreement
to take part in an audio-recorded telephone interview. If they con-
sented to this, their contact details were passed to the qualitative
research team. Randomization between the two arms for the
main study was carried out at this stage, and the outcome noti-
fied to the qualitative research team to enable balanced recruit-
ment across study arms for interviews. Participants were informed
of their randomization at their study site only after the initial
interview was complete, in order that their views at the outset
were unaffected by the arm of the study they were to follow. Par-
ticipants were initially contacted by telephone for interview, in
the order of recruitment to ascertain whether they were still
happy to take part. If they agreed, the interview was carried out
either immediately or an alternative time to call back was
arranged.
Data Collection
Interviews were conducted by one of two researchers, R.C. and
R.M. R.C. is a Clinical Psychologist with experience of undertaking
psychological assessment of patients being considered for SCS.
R.M. is an experienced qualitative researcher at Teesside
2
www.neuromodulationjournal.com © 2020 The Authors. Neuromodulation: Technology at the Neural Interface
published by Wiley Periodicals LLC on behalf of International Neuromodulation Society.
Neuromodulation 2020; ••: ••–••
CHADWICK ET AL.
University with no previous experience of this field. Neither of
them had prior knowledge of any of the participants.
Interviews were conducted by telephone with each participant
at a time that was convenient to them. Two interviews were car-
ried out with each participant—one shortly before their planned
surgery date and a second at least four weeks after the implanta-
tion of the device (four weeks after surgery for one-stage proce-
dure and four weeks after second surgery for two-stage
procedure).
A semi-structured interview guide was used to provide a frame-
work for interviews, to ensure that consistent data were captured
between participants and by each researcher while also allowing
the flexibility to explore issues raised by participants At the start
of the study, a small number of participants had been recruited
and were awaiting implantation before a recording device
became available. To avoid their implantation being delayed, nine
interviews were conducted with contemporaneous notes which
were subsequently transcribed for analysis. All remaining inter-
views were audio-recorded and transcribed verbatim for analysis.
Interviews lasted between 10 and 40 min.
Participant Rated Preferences
In addition to undertaking telephone interviews, participants
were asked in conclusion to express their overall preference for a
one-stage (1#) or two-stage (2#) procedure on a 5-point scale:
Strongly prefer 2#/Prefer 2#/No preference/Prefer 1#/Strongly
prefer 1#.
This was carried out at the end of both preimplant and post-
implant interviews. At the preimplant interviews, participants
were unaware of the trial arm to which they would be random-
ized, so their preference could not be influenced by this
knowledge.
Ethical Approval and Conduct
This study received a favorable ethical opinion from the UK
Health Research Authority’s North East – Tyne and Wear South
Research Ethics Committee (REC reference 17/NE/0056).
Sample Size
In qualitative research, sample size is determined by the ability
to explore participants’ experiences in-depth (15). Qualitative data
analyses do not impose restrictions on overall sample size, and
even small samples can yield large amounts of meaningful
data (16). Data from 31 participants are included within the analy-
sis, representing 31 interviews carried out prior to device implan-
tation and 23 interviews carried out at least four weeks after
device implantation.
Each participant consenting to be interviewed was contacted
via telephone up to three times. If they were not available and
had an active voicemail service, a message was left giving contact
details of the research team should they wish to participate. On
the third attempt, it was explained that no further calls would be
made. The same three call procedure was adhered to for the
follow-up interview as well. All participants contacted were willing
to take part in the interviews.
It was intended to recruit ten participants from each of the
three study sites, five undergoing a one-stage procedure and five
undergoing a two-stage procedure with a total recruitment target
of 30 participants (n = 15 one-stage and n = 15 two-stage).
Analysis
In keeping with the exploratory nature of the qualitative study,
data were analyzed utilizing an inductive approach, rather than
applying a priori themes to the data. Initial analysis of a sub-set of
transcripts from both sets of interviews (preimplant and postimplant)
was undertaken collectively between the qualitative research team
to ensure that findings were credible, valid, and shared (17). NVivo
10 software was used to facilitate the management of data.
A six-stage thematic analysis strategy was employed (18,19).
Stage one: familiarization was undertaken by the qualitative
research team. R.M. reviewed the entire data corpus by listening
to the tapes and reading the transcripts. R.C. and H.S. reviewed a
proportion of the interview transcripts each (three preimplant
interviews and three postimplant interviews). Stage two: initial
codes were generated by the three researchers independently.
Stage three: the team then met to discuss the initial codes and to
develop initial themes. Stage four: R.M. applied the initial themes
to the entire data corpus. Stage five: themes were reviewed and
refined to ensure a good fit with the data. These final themes
were reviewed by R.M., R.C., and H.S. before being defined and
named. Stage six: finally, the themes and sub-themes were pres-
ented and reported by describing them using selected direct quo-
tations from participants for illustrative purposes.
RESULTS
Thirty-one individuals across all three trial sites participated in
the initial preimplant interviews, representing 16 participants due
to undergo a one-stage procedure and 15 due to undergo a two-
stage procedure (Table 1). Eight participants were lost to follow-
up, four who underwent a one-stage procedure and four who
underwent a two-stage procedure.
The following findings are separated into two main sections.
First, findings of the initial preimplant interviews are presented,
where participants discussed their preferences for either a
one-stage or two-stage procedure. Second, findings from the post-
implant interviews are presented, where participants discussed
their reflections on their experiences of undergoing the procedure.
Findings From the Preimplant Interviews
Two main themes arose from the initial interviews: expectations
of SCS and preferences for a one-stage or two-stage procedure.
The second theme included a number of subthemes, all reflecting
reservations about the two-stage procedure: the prospect of hav-
ing “loose wires,” the additional time and support requirements,
and the need to save National Health Service (NHS) resources.
Expectations of SCS
Participants discussed their hopes that SCS would improve their
quality of life in general terms. Their current experience of persis-
tent pain had widespread impact on many daily activities. Many
participants noted that their pain interfered with their sleep, leav-
ing them exhausted both mentally and physically; their social
lives; and their ability to maintain paid employment.
It restricts everything, what you can do. I can’t walk as far
as I used to. You know, I’ll get pain when I’m travelling, that
kind of thing. So it’s just generally restrictive. You can’t
sleep, I’m woken up in the night. (010)
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Another participant added:
I’m not getting much sleep…. it’s affecting my life full stop.
I can’t work and its affecting my… social life. I don’t go any-
where really. (019)
For participants who were in intimate relationships, their persis-
tent pain had affected their interactions with their partners. For
some the persistent nature of the pain had caused them to
become irritable and lash out at those closest to them.
And my partner is here, so I can say, I’d better say I get very
grumpy with it! [the pain]. She’s nodding her head vigor-
ously. (010)
These far-reaching implications of living with persistent pain
led participants to explore what their expectations were, in
terms of the changes they hoped SCS would achieve. All par-
ticipants expected that the implantation of SCS, regardless
whether a one-stage or two-stage procedure, would reduce
the level of pain they experienced to manageable levels, and
allow them to take part in everyday activities once more.
None of the participants in our sample discussed the removal
of pain completely:
Well, it’s pain reduction. It will therefore allow you to do,
you know to lead a more normal life. It’s not getting rid
of the problem, so you’ve still got to be careful. You
know it’s not a matter of suddenly…. not doing a lot of
walking, and suddenly deciding to go yomping in the
Scottish Highlands, I don’t think you can achieve that! So,
you have to be mindful that it’s taking away the pain
but not the problem. (010)
Another participant added:
I’m hoping that…. every day there’s something now. Every
day I’m, you know, I’ve got some pain or discomfort or
something. And I’m just hoping that, even if we’re talking
about it in terms of pain, I’m hoping that at least half the
week is fine and allows me to do more. (049)
Preferences for One-Stage or Two-Stage Procedure
When participants were asked to explore their preferences for
either a one-stage or two-stage procedure they stated over-
whelmingly a preference for a one-stage procedure. It was unclear
to many if or why an individual would opt for a two-stage proce-
dure if a single stage was an option. One participant noted:
You know, I can’t [understand why] there’s any reason why
people wouldn’t want a 1-stage rather than a 2-stage. (038)
Another participant expanded:
No. Really, no, I can’t see [advantages to 2-stage]. I mean
I’m an engineer. I work on process development, work on
production systems. There’s no benefit to opening some-
body up. Putting a system in, trying it, and then saying do
you want it or not? And then redoing it all again. You might
as well put it in, does it work? Yes? If it does – off you
go. Happy days! If it doesn’t – take it out anyway. (027)
Nonetheless participants were invited to consider both the bene-
fits and disadvantages of undergoing either a one-stage or two-
stage procedure more fully.
Loose Wires. The practicalities of having a two-stage procedure,
especially living for a week with wires hanging externally to the
body, gave cause for concern. Many participants were fearful that
they, or someone else, would accidentally dislodge the wires and
ultimately invalidate the trial period:
My main concern is that I do something to mess it up, with
regards to the trial, I’m worried I would move the
wire. (011)
From the positive point of view having a 1-stage would
mean you have nothing hanging outside of the body and
having to wear it on a sort of strap arrangement for a week.
(038)
I think it’s the fact that…. it’s sort of on the outside of your
body and it’s more…… you’ve got to be probably more
careful that you might snag the leads (061).
In addition to fears about moving or knocking the external leads,
some participants raised concerns about the distance needed to
travel back to the hospital to receive medical attention:
So if anything happens, you know, with the wires and
things like that it’s a long distance going back…what if
they come out? What if the…. you know, what if anything
happened with them? (067)
Time Needed (Two-Stage). Taking time out of daily life to
attend two episodes of surgery was raised as a concern repeat-
edly by participants. Time taken off work was a worry for some.
When presented with the choice of one or two surgical proce-
dures, taking time off work to attend the appointments and for
the subsequent recovery, having a single-stage procedure was
the more attractive option:
For me it’s about the time off work – being self-employed.
Because you’re having to go through two procedures, two
times off work, everything else. And with my work being
kind of seasonal, and dependent on weather, when we get
good weather I don’t want to be laid up. (037)
Many participants lived long distances from the hospital sites that
they would need to attend. Traveling to and from presurgical
4
Table 1. Number of Participants by Trial Site and Study Arm.
One stage Two stage Total
Preimplant Postimplant Preimplant Postimplant
Site 1 5 4 6 5 20
Site 2 5 4 5 3 17
Site 3 6 4 4 3 17
Total 16 12 15 11 54
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appointments, then again for two surgical appointments was
daunting for them:
The other reason, which is purely selfish, is that I live a
good few miles away from where the hospital is. It’s quite a
drive. And as I’ve said before driving is not the best. (038)
This was not only due to distance but because participants
would have to rely on the good will of friends and family to drive
them to and from these appointments. Participants did not want
to put undue burden on those people:
It’s such a, it’s a long way to go, and I’ve got to, you know
if I go in on the first time I’ve got to get somebody to take
me in. then I’ve got to get somebody to take me back.
Then the second time, I’ve got to get somebody to take me
in, and the second time to take me back again. (018)
Support Needed. For some, the main worry was about impos-
ing a burden on others by having to ask for their support, not
only with attending for appointments and treatment but also dur-
ing the period of recovery. As one participant noted:
The extra pressure that it then puts on the family as well.
Because my husband’s got to take a day off work to take
me down there and bring me back, and the kids and, you
know I just think for me I’d rather have it all done in one
day. (043)
Similarly, participants who had children raised the issue of
childcare while they were undergoing surgery. These participants
for very practical reasons stated that they would prefer to have a
single stage procedure so that they did not have to access
childcare for two episodes of surgery and the subsequent
recovery:
I don’t want to have to mess about going to [names hospi-
tal] because I live in [names home town]. So I’ve got to
travel over there to get these procedures done. I’m a single
dad, so you know, it’s not easy for me to get a babysitter
for like two occasions you know. (015)
Saving NHS Resources. Many participants discussed the posi-
tive impacts a one-stage procedure would have on the NHS rather
than them personally. There was acknowledgement that if a one-
stage procedure was the norm, more people could benefit from
SCS as it would be possible to implant more as each procedure
would take less time. One participant explained:
It would be saving costs and time, you know, for the doc-
tors. For other people that’s needing the same thing as
me…..because I know it’s not just me that has this problem.
(032)
There would only be the need for one theater slot per patient, as
this participant stated:
You know there’s only one theatre time, there’s one surgery
time, there’s one risk of infection. Do you know what I
mean? You can increase the amount you’re doing because
you’re only needing one theatre slot. (081)
Another participant expanded on this by noting that for a one-
stage procedure there would be less input from the wider surgical
team, therefore saving money for the NHS:
If it [the device] has to go in twice, then it’s twice they’ve
got the surgeon there, the anaesthetist twice, you know
what I mean? It’s money after money, isn’t it? (018)
Other Perspectives?. While all participants had stated that they
would prefer a single-stage procedure and many noted the per-
ceived benefits of it, each participant was asked whether they
could see any advantages to having a two-stage procedure over a
one-stage. Ease of removal of wires as opposed to the removal of
an implanted battery pack was the main advantage identified.
One participant explained:
They can just take the wires out, that’s it, it’s not for you
and they don’t go any further. Whereas if you have it
implanted in the one go and it’s not for you, it’s gonna be
trickier and potentially a longer process to then have it
removed. (081)
Another participant commented:
Well I suppose the benefit would be that you would kind of
like know it works for you. And you’ve kind of like, you’ve had
a sort of slightly smaller thing done to you in a way (053).
Findings From the Postimplant Interviews
The themes emerging from the second round of interviews
were more highly differentiated, reflecting the direct experience
of the procedure rather than anticipation. These included: the
main outcomes of treatment (largely in line with expectations);
practical living with the SCS device; strange sensations/discom-
fort; the value of information; the importance of consistent after-
care; the need to manage expectations; and further reflections on
the options of one-stage or two-stage procedures.
Main Outcomes
Pain Relief. The vast majority of participants reported that their
pain had been reduced since SCS implantation and for some the
relief had been revolutionary. As one participant explained:
It’s given me back my life again. I wish I’d had it done four
years ago, never gone through all the surgery, treatment.
I was a bit sceptical at first, but when they switched it on…
[participant gasped]. (008)
Another participant commented:
It’s marvellous…well I don’t get sciatic pain anymore…
which is what I was trying to get rid of. (038)
5
Neuromodulation 2020; ••: ••–••© 2020 The Authors. Neuromodulation: Technology at the Neural Interface
published by Wiley Periodicals LLC on behalf of International Neuromodulation Society.
www.neuromodulationjournal.com
TRIAL-STIM: PATIENTS’ VIEW ON SCS TRIALS
While the relief was, in most cases, apparent very quickly post-
surgery many participants noted that they were reminded of the
positive effects each time they either forgot to charge the battery,
or did not switch the device on for some reason. One partici-
pant said:
You know it’s great to get rid of the pain, and to be hon-
est…if I forget to switch it on, or switch it off accidently or I
decide to reduce it down too much, I can soon get that
pain back. (038)
Only a few participants felt that the SCS implant had not been
effective in reducing their pain. One said:
Well the operation etcetera went fine. But it hasn’t made
much difference to the pain. (016)
Medication Reduced. A reduced level of pain was not the only
positive effect of SCS implantation experienced. Participants also
noted a reduction in the number and dose of pain medications
taken. One said:
I’ve reduced my drugs by half… So I’m not suffering the
side effects from the pregabalin as much. (037)
Another stated:
I was on pregabalin for…the sciatic pain. Tramadol, of
course. And I was also taking paracetamol…and ibupro-
fen….To be honest I was on a cocktail of all those on a
daily basis. And immediately I’ve been able to more or less
drop completely paracetamol and ibuprofen. (Now) I’m
generally more alert and more awake…. (038)
Improved Function—Able to Sit Longer, Walk Further. Many
participants experienced benefits of improved function—the abil-
ity to sit for longer periods of time, walking further, enjoying
activities with friends and family, or doing housework. One partici-
pant commented:
I can sit a little bit longer in the car…I can drive a little bit,
well quite a bit further now…I’m also getting out with the
dogs now as well. (019)
Another said:
It’s been amazing to actually have a life….Even just sweep-
ing the floor…Making food, you know, EVERYTHING! (067)
Other comments included:
I’m standing more, sitting more, walking more. (081)
On a day to day basis I can now say, right we’re gonna do
stuff. We’re gonna go places… you know I’ll play with the
grandchildren, I can do stuff, and be part of the family.
Which I wasn’t being for the last few years particularly, I’ve
been pretty much laid up. (038)
Made a huge difference to sleep - able to sleep much lon-
ger than before. Fantastic. (004)
Observations of Change by Family Members. For several par-
ticipants, improvements were not only experienced by themselves
but also by their friends and family. As this participant explained:
Because I must admit when you’re in pain for such a long
time you can become a miserable git. And I think it’s just
frustration, just because the pain’s so….it just drives you
nuts. Even me wife said, you’re a lot happier these days.
You seem a lot happier. You’re not as…fed up with every-
thing. (037)
Another commented:
Well I’m…not able to do more as such. But.. I can go out
and sit for lunch. Take for example Friday, I went out for
lunch with my Mum. Before I’d be sitting there in agony.
And I wouldn’t really say a lot. And my niece noticed that I
was a lot more bouncy and happier and, and not writhing
in pain……. A huge difference.. (087)
Practical Living With SCS
One new theme emerged as a consequence of practical experi-
ence of day to day life with an implanted device. Two main areas
were highlighted: the ability (or otherwise) to change the settings
of the device to relieve pain; and participants’ experiences of
charging the device.
Ability to Change Settings. Some participants in the study had
the facility to change the settings of their own device and cycle
through the programmes to find those which gave most relief.
Others had to have the settings changed by a health professional
at a hospital appointment. Participants noted that the relief from
each setting was not necessarily long-lived and that “cycling”
through different settings offered them the opportunity to experi-
ence continued relief. As one participant described:
I’ve been messing about with power settings. But since I’ve
found settings that I’ve liked, I’ll stick on a setting for about
a week, ten days. And then I’ll change it to another one.
Because you seem to get used to it…and then I change to
another one and it seems alright then swap back.…that
seems to control the pain… (037)
Other participants commented:
I’m changing the programme every three days, keeping a
diary and going back for review… So far, I’ve found three
programmes that I’m comfortable with. (008)
I’ve got a couple of settings that I’ve got preference
on. And I sort of just alternate every other day, between
the two. (019)
I barely notice it now [pain]. I do notice it if I have to turn it
up, as I said. And a couple of times I’ve got to a point
where I’ve had to turn it up, but it physically stops me from
walking… (032)
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Participants who were unable to change their settings themselves
felt frustrated that they had to wait to go back to the clinic to
have the setting changed and experience pain relief. As one par-
ticipant below noted:
I’ve had the ‘ump today because I’ve not been able to
change me setting. I’m back in [clinic] again tomor-
row. (067)
Charging the Device. Participants also discussed their experi-
ences of charging the device. One noted feeling better when the
device was fully charged:
Sometimes I feel more wiped out than normal, when the
battery’s running down. I feel better when it’s fully
charged. (008)
Regular charging of the device is necessary to ensure pain relief:
If I don’t keep it plugged in the battery turns off. You can
feel a difference then. (016)
However, most participants explained that the process of charg-
ing had a relatively low impact on their lives, and for some it
offered an opportunity for “me time.” As one participant noted:
It’s no trouble at all. I’m catching up with the touring car
racing that was on yesterday on the tele’…So I’m watching
a couple of those races while I’m just charging me battery
up. So that needs doing every three or four days…It takes
an hour and half, two hours maybe. And I can move around
while it’s doing it. But you know I’m quite happy to sit and
watch a programme while it’s happening. (038)
Sensations and Discomfort
Strange Sensations. Some participants described experiencing
strange sensations which they had not expected since having a
device implanted. Some reported electric feelings through
their body:
From the waist down, you know I could feel it, everything
firing. Like electrodes. I could feel them all firing from all
over the lower half of me body. It was [strange] to start
with. And I’ve got used to it now. (032)
Another added:
I’m quite happy putting up with the [sensations], at the
moment I’ve got the sort of tingling electrical shock up my
legs and everything. And that me tells me that it’s work-
ing… I’m quite happy to feel that…You know I’d much
rather have that than pain. (038)
Battery/Lead Positions. The positioning of the battery pack
underneath the skin and the wound site had the potential to
cause new acute pain for participants. As one participant noted:
The only other problem that I’m having is that around the
anchor sites for the leads, the doctor explained that they’d
been stitched in over a little tube…I’m getting quite a lot
of pains from that. Particularly when I’m driving… (026)
Others were aware of pain and attributed it to different aspects of
having a foreign object in their body. As one participant
explained:
But sometimes that area hurts where it is, and where the
two wires go into your spinal cord. That’s painful as well
every now and again. (016)
Some participants felt that the battery moved around a little in
the cavity:
I think the only problem, the main problem is obviously
once you’ve been sat for a while it sort of pushes it up if
you know what I mean. And probably causes us, why then I
get the pain. (067)
While others experienced pain when applying pressure to
the site:
The only thing I still struggle with is lying flat on my back…
and sitting in a hard back chair. Anything that puts direct
pressure onto the battery. (081)
Value of Information
It was clear from the interviews that participants valued having
as much knowledge or information as possible—whether from
other patients, or through their own research. They also thought
highly of clinical staff being willing to communicate with them
openly.
From Other Patients. Some participants had the opportunity
to speak to other people who had undergone the procedure prior
to their own treatment. The opportunity to ask questions and
receive honest answers and advice from those with experience
was seen as very helpful. One of the trial sites offered this oppor-
tunity in the form of a support group for prospective and former
patients to provide a forum for advice. One participant dis-
cussed this:
I thought that was an absolutely fantastic idea…It is really,
really good that patients can actually meet patients that
have had it done. And see real people with it, and ask
proper questions. Because if somebody asked me does it
hurt when you have it fitted, I’ll just tell them, yeah it does.
It’s bloody awful for about two or three weeks. It’s awful,
but you get used to it. (037)
Other participants had sought support through online forums,
which acted as a network to compare experiences:
I met another lady on a forum who I talk quite a lot with.
And she had it done the other way [two-stage procedure].
And her journey just seems so much longer than mine. She
was all taped up and stuff in all that heat. So she was really
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uncomfortable, and sweating and reacting to the tape. And
had all these extra issues that I didn’t have by having it
done in one go. (081)
Internet Research. Participants utilized the internet not only for
support from others who were having similar experiences but also
to gain knowledge about what to expect. However, researching
the Internet did not always uncover success stories to provide
reassurance:
[I] knew what to expect. I didn’t search for information too
early, till I knew it was going ahead. I’m aware that online
you see the bad - horror stories - more than the
good. (004)
Another participant added:
I actually had a few thoughts of … what if it doesn’t work?
Because a lot of people say that once you’ve had the trial
that works, but if it works for you then normally the perma-
nent implant doesn’t work. You know when you’ve read all
different stories? And I was a bit apprehensive. But straight
away it worked for me. (067)
Importance of Consistent Aftercare
All participants were happy with the aftercare they had
received from the trial site teams. One participant explained:
They bend over backwards and they’re very helpful going
through it all. And you know I’m very happy with what the-
y’ve done. (019)
However, some participants, who lived some distance from the
trial sites, explained that accessing aftercare could be trouble-
some, especially if out of hours. If advice was needed in relation
to SCS, participants were likely to seek support from healthcare
services local to them. As one participant stated:
I did have a concern at one point, me scar was very purple.
And well it was very pink at one bit, and very purple in
another bit. But I sought advice at the hospital here at
[local hospital] just to be on the safe side, it wasn’t like a
wound infection. I know they’d told us to go to the [trial
site] if there were any problems. But it was a weekend and
obviously there’s nobody in Pain Management at the week-
end. So I just popped up there, and the Nurse Practitioner
had a look and said, no it looks fine. (019)
Need to Manage Expectations
In the initial interviews, many participants had acknowledged
that having an SCS implanted was not a guarantee that their pain
would be removed completely. Many were realistic in their expec-
tations, hoping simply for significant pain reduction. However,
several participants noted in their follow-up interviews that SCS
was not living up to their hopes. One participant discussed the
positive and negative effects of SCS:
It’s definitely [made a difference] - the stimulation hasn’t
been able to reach my foot, the main problem - but the
knee to the ankle is not as severe, [there are] fewer cramps
and spasms. I’ve had none at all since the permanent
implant – I was having them every night. (004)
Another said:
Overall it’s, I’m not disappointed. Well I am and I aren’t. It’s
better than nothing. It’s doing a bit of good which I’m
grateful for. (016)
A few participants felt that the SCS was not working for them at
all. One described their disappointment:
Absolutely devastated that it didn’t work. Never expected
for a moment that it wouldn’t. I was waiting for it every
day. (003)
Another stated:
No, well apparently it only works for about eighty percent
of the people it’s put in. I must be one of the twenty
percent-ers. (016)
Preferences: One Stage vs. Two Stage
As in the initial interviews, the vast majority of participants still
felt that having a single stage procedure was preferable. The sub-
themes clustered around practical differences between the two
options, similar to those anticipated at the outset: the benefits of
having everything done at once, including a single period of
recovery; and the awkwardness of having “loose wires.” However,
there was one additional concern: recognition that the surgical
procedures were more serious and required more healing than
expected.
Benefits of Having It All Done at Once. Participants who had
undergone the one-stage procedure were generally happy about
it, for all the reasons outlined above. One participant discussed
how having a single procedure prepared you mentally for
success:
You know, it was a real big difference from that point of
view. And I just think psychologically you go in once; do you
know what I mean? And if you’re having the trial there’s an
element of failure of that to me. Because you’re going to trial
something that may work, or might not work (081)
Others were happy to have just one period of recovery:
I think it’s always better just to have one operation
really. (026)
And to have just one hospital admission:
Just the one admission to hospital, do you know what I
mean? Just the one procedure. And obviously…it’s kind of
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infections and all stuff like that from a medical point of
view. But just me only having to go in once. (081)
On the other hand, participants who had undergone the two-
stage procedure discussed the added costs in terms of time and
finances to attend two appointments—for the trial and the per-
manent implantation.
You know, just simply from the fact that it’s a day proce-
dure, but I had to be nearby the hospital to have it
checked. We had to book accommodation nearby…there’s
double the costs for a start…And that’s, you know, that
would not be needed if it was a one stage procedure. (038)
Loose Wires. Participants who had undergone the two-stage
procedure discussed and confirmed similar concerns to those
raised in the preimplant interviews. Many found having wires
external to the body for a prolonged trial period quite uncomfort-
able and feared they might dislodge them. One participant
explained:
I was [scared of] catching it on things. Like just coming
from the bathroom. I was coming, I can’t remember if it
was the bathroom door or the bedroom door. I’d stopped
to do something and turned. And of course the handle got
among the wires, and luckily my wife spotted it. Otherwise
I would have pulled them! But just like for, wearing clothes
and that as well. That was sort of bulky. (019)
Another explained:
So I had to walk around with wires dangling out me back
into the remote unit on me belt…it was a bit awkward, you
know, my whole back with covered with plaster. So it was a
bit itchy and a bit uncomfortable. But it was alright. I think
if, you know if I’d been given a choice, I’d have probably
opted to have it done all in one go (038)
Aside from concerns about dangling wires, one participant wor-
ried about the risk of infection between the two procedures:
I don’t know but you can imagine there’s more of a chance
of infection doing it that way as well. Opening a wound…
with the two-stage procedure. Because you’re leaving the
hospital with actual wires hanging out of you. (038)
This Is Serious Surgery. In the preimplant interviews there was
little consideration of the extent and potential impact of the sur-
gery. However, at follow-up several participants considered that
they had undergone major surgery—something they had not
quite understood previously. One participant stated:
I had it put in in two stages - then another operation to have it
taken out. I didn’t realise they were such big operations. (003)
Another participant said:
Whatever they tell you, they’re not minimal procedures.
They’re quite, you know quite painful, and they’re quite
uncomfortable. And, you know, it takes a little while to heal
afterwards. But the results really seem to make it absolutely
worthwhile. (038)
Other Perspectives. Despite the overwhelming support for a
one-stage procedure, one participant who had undergone this
and not experienced any benefit discussed their ambivalence
about which procedure would have been preferable:
I suppose I’ve had the disadvantage of not seeing how well
it works before going for the full operation. And given the
fact that it doesn’t seem to have worked that well in me, I
don’t know whether maybe that would have meant that I
would have not had the full procedure? And, therefore, that
I might not have gone through so much. (026)
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Another stated:
I would have hated to have, hated, hated, hated to have
had it put in and have been no better off. To have gone
through that… (019)
Participant Rated Preferences
At the end of both preimplant and postimplant interviews, par-
ticipants were asked to express their overall preference for a one-
stage or two-stage procedure on a 5-point scale:
Strongly prefer 2-stage/Prefer 2-stage/No preference/Prefer
1-stage/Strongly prefer 1-stage.
Their responses are given in Table 2. The arrows indicate the
relationship between preimplant and postimplant preferences for
each individual. It is of note that 26 of 31 participants expressed a
strong preference for a one-stage procedure preimplant (16 ran-
domized to one-stage and 10 to two-stage). Of these 26, 17 par-
ticipants were of the same opinion postimplant (12 having
undergone one-stage and 5 having undergone two-stage). Seven
were lost to follow-up. In addition, three participants expressed a
preference for one-stage at preimplant interview, increasing to a
strong preference for one-stage at postimplant (all having under-
gone two-stage).
Only one participant expressed a preference for two-stage at
preimplant interview (and was then lost to follow up). And only
two participants changed their opinion away from one-stage.
DISCUSSION
The findings indicate an overwhelming preference among par-
ticipants for a one-stage SCS procedure both before and after the
implant, regardless of which procedure they had undergone.
Themes emerging from the interviews about the reasons for
this preference are broadly similar between preimplant and post-
implant time points. Both before and after, themes favoring the
choice of the 1-stage option include: saving time (off work, in hos-
pital, attending appointments); avoiding the worry about having
“loose wires” and the impact this may have in the two-stage
procedure—in other words, an external wire which could snag on
something, or become dislodged; and saving NHS resources (doc-
tors’ and other staff’s time, medical devices and materials). In
addition, a theme from the postimplant interviews reflects the
advantage of having only one surgical intervention, and one
period of recovery. There is a sense that some participants had
not fully grasped the extent of the intervention, or the separate
acute pain and length of healing involved.
Of those participants who changed their opinion following the
implant (six in total), only two moved away from a preference for
a one-stage procedure (see Table 2). Both these participants origi-
nally expressed a strong preference for a one-stage procedure
but were then randomized to a two-stage procedure. One of
these changed to a mild preference for two-stage, commenting:
“I’ve changed my mind a little - it’s better to try it. It’s a lot to go
through if it doesn’t work.” The other was deemed on balance to
have changed to a neutral response, commenting: “I still like one
procedure to be honest. Not being able to shower [with 2-stage]
…. I’m 50-50 really.”
In addition to these novel findings, a number of general themes
emerged from the interviews which are in line with previous studies.
First, the value of knowledge and information for SCS patients from
a variety of sources was strongly emphasized (contact with other
patients, selective internet searching, advice from staff). Similar con-
clusions are reached by earlier qualitative studies including Sparkes
et al. (20) highlighting the value of access to expert patients; Gjesdal
et al. (21) pointing out the important role of the nurse; and Ryan
et al. (22) incorporating a list of practical information needs for SCS
patients. There is clear agreement that reliable information is of cru-
cial value, enabling people to form their own opinions and develop
a framework to support their own decision-making.
Second, SCS is neither a complete cure for pain nor is it a
standalone treatment. There is a continuing need for the individ-
ual to engage with coping strategies, and preferably to receive
preparation for this beforehand. There is likely to be ongoing dis-
comfort, as well as unusual sensations. Also depending on the
type of device implanted, the individual may need to adapt to a
regular routine of re-charging the battery. For all these reasons,
there is a need for personal adjustment to a different way of life,
involving effort to manage expectations of the treatment. Again,
similar points have been made by previous studies. Henssen et al.
(23) refer to the constraints and possible disadvantages of SCS.
Gjesdal et al. (21) draw attention to the challenges in adaptation
to everyday life with SCS; and Turner (24) suggests that psycho-
logical intervention in conjunction with SCS may support the pro-
cess of adjustment, and improve outcomes. A recent systematic
review of qualitative research into patients’ experiences of
neuromodulation concludes that adjuvant psychological therapy
should form part of an overall pain management plan, including
provision for ongoing emotional and psychosocial support (25).
Third, in relation to the procedure itself (implantation of the
device, with or without a trial), the severe acute pain and length of
physical recovery had a significant impact for many participants,
and this was a factor contributing to their preference for a one-
stage procedure. Participants were more inclined to want only to
go through the procedure once. Sparkes et al. (20) have previously
acknowledged the discomfort associated with the treatment, which
may come as a shock without adequate preparation beforehand.
Finally—and despite the limitations of SCS—the themes indicate
that treatment outcomes are broadly in line with prior expecta-
tions. Preimplant interviews suggest that expectations include pain
reduction (not elimination); improved mobility; increased participa-
tion in daily activities; and improved quality of life. Postimplant
interviews reveal a similar pattern of outcomes, with reduction in
pain evidenced in some cases by a decrease in medication. Earlier
studies have arrived at similar conclusions—Henssen et al. (23)
relating to expectations; Han et al. (26) to SCS outcomes; and Ryan
et al. (22) to both. The present study also has one new finding in
relation to outcomes—namely that beneficial changes may be
observed favorably by family members, which appears to be a
powerful reinforcer. Not only is there the prospect of a reduced
level of pain, with increased activity and improved quality of life;
there is also the satisfaction of seeing family members appreciating
these benefits and possibly sharing in reduced burden.
One additional point worthy of comment is the concern
expressed by participants both preimplant and postimplant for
saving NHS resources, by having a one-stage procedure. The sav-
ings were related to staff time and equipment. In the context of
SCS, we believe this to be a novel finding. It is possibly due in part
to the structure of interview questions in this study (with an
explicit focus on advantages and disadvantages of the two proce-
dures); and in part to the current frequency of media reports on
pressures within the NHS.
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Strengths and Limitations
To our knowledge, this is the first study to investigate patients’
preferences about whether to undergo an SCS screening trial
prior to permanent implantation. We sampled opinion across all
three centres involved in the trial, and consequently our findings
can be generalized to UK practice. Participants were drawn from
both arms of the study, screening trial and no trial, and interviews
were undertaken both before and after SCS implantation, giving
the widest possible range of perspectives. The initial interviews
were carried out before participants were aware of the arm to
which they had been randomized, with the intention of removing
potential bias due to expectations.
The study also has some limitations. It was intended that
follow-up interviews should be carried out four weeks after com-
plete SCS implantation. However, due to variations in practice
among the three centres this was not always achieved, and some
follow-up interviews took place up to eight weeks after implanta-
tion. In consequence, these participants had a longer recall time.
Also it was not possible to re-establish contact with eight partici-
pants after implantation, and they were lost to follow-up. Further-
more the follow-up interviews conducted did not include a
participant who had failed a screening trial, so it was not possible
to consider this perspective.
Policy and Practice Implications
The findings of this study have potential implications for both
policy and clinical practice:
• From the patient perspective, there is a clear preference for a
single-stage SCS implantation procedure without a preimplant
trial period. In conjunction with the quantitative results from
the trial, this is relevant to consideration of the future policy
framework for SCS.
• Informational needs of patients undergoing SCS remain a high
priority, with a balanced approach to multiple resources includ-
ing expert patients.
• Specific preparation both for the procedure itself, and also to
assist adjustment to the realities of living with SCS, should form
an essential aspect of patient care.
• Appropriate support to patients (including psychological inter-
vention) should be considered throughout preparation and
follow-up care, to optimize their prospects of benefitting from
the treatment and having improved quality of life.
CONCLUSION
The results of this qualitative study indicate that patients who
undergo SCS for the management of neuropathic pain have a
strong preference for a one-stage procedure, bypassing the cur-
rently required screening trial. These findings further support the
results reported by the TRIAL-STIM RCT. In addition to screening
trials not providing patient benefit and not representing value for
money, patients would prefer not to have a screening trial prior
to implantation of the SCS device.
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COMMENTS
This article is really interesting. It represents the patients’ point of
view, and evaluates multiple aspects of both expectations and prefer-
ences on the type of procedure to be performed (single or two
stages). I think these results were predictable, considering the lower
risk of infection, fewer surgeries, difficulty in reaching the hospital
etc. It is also necessary to evaluate other aspects of health econom-
ics. What is the point of view of scientific societies regarding the
trial? What are the reimbursement criteria for the procedures? Is the
one-stage procedure really convenient, from the point of view of
reimbursement, for hospitals? The possibility of offering different
stimulation modalities could allow the use of the one-stage proce-
dure in the majority of patients. This concept is certainly even more




This is a very interesting paper that looks at patients’ preference for
either a 1 or 2 stage SCS procedure. The patients’ responses were
interesting and revealed information that has not been discussed pre-
viously, like the patients’ concern about the impact on the healthcare
systems and the value of discussing the procedure with patients who
had undergone the procedure prior. Finally, is was interesting that
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